ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Similar Posts
Maria A. Carballosa, M.D. – 720805 – 12/12/2025
In Vivo Bioavailability-Bioequivalence Studies – ClinicalCommissioner’s National Priority Voucher (CNPV) Pilot Program Submission
This new pilot program is designed to accelerate the development and review of certain drugs and biological products that are aligned with U.S. national health priorities and to enhance the health interests of Americans.Azurity Pharmaceuticals, Inc. – 656489 – 09/20/2024
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugNefeteri Wellness – 709332 – 05/30/2025
Unapproved New DrugsSumitomo Pharma Co., Ltd. 8/7/2025 483
Record Date: 08/7/2025
Entity Name: Sumitomo Pharma Co., Ltd.
FEI Number: 3003028650
Record Type: 483
Country: Japan
Establishment Type: Drug ManufacturerAnesthetic Vaporizer Recall: Draeger Removes Vapor 2000 and Vapor 3000 Vaporizers
Draeger is removing certain Vapor 2000 and Vapor 3000 Vaporizers due to impurities found within a component.